AAV2-mediated interleukin-12 in the treatment of malignant brain tumors through activation of NK cells

International Journal of Oncology

Volumn 35, Issue 6, 2009, Pages 1361-1367

  Chiu, Tsung Lang ^a,b   Lin, Shinn Zong ^c   Hsieh, Wan Hua ^a   Peng, Chih Wen ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adeno associated virus; Cytokines; Gene therapy; Glioblastoma multiforme; Immunotherapy; Interleukin 12

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; INTERLEUKIN 12; PARVOVIRUS VECTOR; TUMOR NECROSIS FACTOR ALPHA; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL ACTIVATION; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; GENETIC TRANSDUCTION; GLIOBLASTOMA; GROWTH RATE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; TUMOR GROWTH; ADENO ASSOCIATED VIRUS; ANIMAL; BLOOD; BRAIN TUMOR; DRUG SCREENING; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; GENE THERAPY; GENE VECTOR; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DEPENDOVIRUS; FLOW CYTOMETRY; GENE THERAPY; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-12; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73949142444     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000454     Document Type: Article

References (23)

1. Daneyemez M, Gezen F, Canakci Z and Kahraman S: Radical surgery and reoperation in supratentorial malignant glial tumors. Minim Invasive Neurosurg 41: 209-213, 1998.
2. Kayama T, Kumabe T, Tominaga T and Yoshimoto T: Prognostic value of complete response after the initial treatment for malignant astrocytoma. Neurol Res 18: 321-324, 1996.
3. Kowalczuk A, Macdonald R, Amidei C, Dohrmann G, Erickson R, Hekmatpanah J, Krauss S, Krishnasamy S, Masters G, Mullan S, Mundt A, Sweeney P, Vokes E, Weir B and Wollman R: Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 41: 1028-1036, 1997.
4. Dredge K, Marriott J, Todryk S and Dalgleish A: Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol Immunother 51: 521-531, 2002.
5. Fehniger T, Cooper M and Caligiuri M: Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine Growth Factor Rev 13: 169-183, 2002.
6. Watford W, Moriguchi M, Morinobu A and O'Shea J: The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 14: 361-368, 2003.
7. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133-146, 2003.
8. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ and Ryan JL: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90: 2541-2548, 1997.
9. Salem M, Gillanders W, Kadima A, El-Naggar S, Rubinstein M, Demcheva M, Vournakis J and Cole D: Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. J Interferon Cytokine Res 26: 593-608, 2006.
10. Ma H, Lin S, Chiang Y, Li J, Chen S, Tsao Y and Xiao X: Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. Gene Ther 9: 2-11, 2002.
11. Mueller C and Flotte T: Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 15: 858-863, 2008.
12. Chirmule N, Propert K, Magosin S, Qian Y, Qian R and Wilson J: Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6: 1574-1583, 1999.
13. Halbert C, Miller A, McNamara S, Emerson J, Gibson R, Ramsey B and Aitken M: Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum Gene Ther 17: 440-447, 2006.
14. Nakai H, Yant SR, Storm TA, Fuess S, Meuse L and Kay MA: Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 75: 6969-6976, 2001.
15. Dong J, Fan P and Frizzell R: Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 7: 2101-2112, 1996.
16. Emborg M, Carbon M, Holden J, During M, Ma Y, Tang C, Moirano J, Fitzsimons H, Roitberg B, Tuccar E, Roberts A, Kaplitt M and Eidelberg D: Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab 27: 501-509, 2007.
17. Chmielarczyk W, Engler H, Ernst R, Opitz U and Kirchner H: Injection of anti-thy-1.2 serum breaks genetic resistance of mice against herpes simplex virus. J Gen Virol 66: 1087-1094, 1985.
18. Karupiah G, Blanden R and Ramshaw I: Interferon gamma is involved in the recovery of athymic nude mice from recombinant vaccinia virus/interleukin 2 infection. J Exp Med 172: 1495-1503, 1990.
19. Hioki K, Maruo K, Suzuki S, Kato H, Shimamura K, Saito M and Nomura T: Studies on beige-nude mice with low natural killer cell activity 1. Introduction of the bg gene into nude mice and the characteristics of beige-nude mice. Lab Anim 21: 72-77, 1987.
20. Kay MA and Nakai H: Looking into the safety of AAV vectors. Nature 424: 251-251, 2003.
21. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, Tai SJ, Ragni MV, Thompson A, Ozelo M, Couto LB, Leonard DGB, Johnson FA, McClelland A, Scallan C, Skarsgard E, Flake AW, Kay MA, High KA and Glader B: AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101: 2963-2972, 2003.
22. Fukui H, Overton W, Herberman R and Reynolds C: Natural killer cell activity in the rat. VI. Characterization of rat large granular lymphocytes as effector cells in natural killer and antibody-dependent cellular cytotoxic activities. J Leukoc Biol 41: 130-142, 1987.
23. Terme M, Ullrich E, Delahaye N, Chaput N and Zitvogel L: Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol 9: 486-494, 2008.